Armata Pharmaceuticals (ARMP) vs Tenaya Therapeutics (TNYA)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Armata Pharmaceuticals (ARMP) has outperformed Tenaya Therapeutics (TNYA) over the past year, gaining 19.9% versus a loss of 70.3%. Over five years, ARMP leads with a +11.9% price change compared with -97.4% for TNYA. Armata Pharmaceuticals is the larger company by market cap ($143.5 million vs $122.0 million), about 1.2 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ARMP | TNYA |
|---|---|---|
| Share price | $3.86 | $0.5442 |
| Market cap | $143.52M | $122.03M |
| 1-day change | +1.31% | +2.02% |
| YTD return | -38.54% | -23.57% |
| 1-year return | +19.88% | -70.26% |
| 5-year return | +11.88% | -97.35% |
| EPS (TTM) | $-5.29 | $-0.52 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $16.34 | $2.35 |
| 52-week low | $3.14 | $0.521 |
| Distance from 52-week high | -76.38% | -76.84% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +353.37% | +488.02% |
| Average volume | 208.13K | 2.27M |
| Shares outstanding | 37.18M | 224.23M |
| Employees | 61 | 70 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- ARMP has outperformed TNYA by 90.1 percentage points over the past year.
About Armata Pharmaceuticals
ARMP stock →Armata Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company that focuses on the development of targeted bacteriophage therapeutics for antibiotic-resistant infections worldwide.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 61 employees
About Tenaya Therapeutics
TNYA stock →Tenaya Therapeutics, Inc., a clinical-stage biotechnology company, discovers, develops, and delivers therapies for heart disease in the United States. Its lead product candidate includes TN-201, a gene therapy for myosin binding protein C3-associated hypertrophic cardiomyopathy that is in Phase 1b/2 clinical trial; TN-401, a gene therapy for plakophilin 2-associated arrhythmogenic right ventricular cardiomyopathy, which is in Phase 1b/2 clinical trial; and TN-301, a small molecule histone deacetylase-6 for heart failure with preserved ejection fraction that is in phase 1 clinical trial.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 70 employees
ARMP vs TNYA FAQ
Which is bigger, Armata Pharmaceuticals or Tenaya Therapeutics?
Armata Pharmaceuticals (ARMP) is larger, with a market capitalization of $143.52M compared with $122.03M for Tenaya Therapeutics (TNYA).
Which stock has performed better over the past year, ARMP or TNYA?
ARMP returned +19.88% over the past 12 months, compared with -70.26% for TNYA (price return, excluding dividends). Past performance does not predict future results.
Are Armata Pharmaceuticals and Tenaya Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.